Drug class in one race
EGFR x c-MET drugs for Non-Small Cell Lung Cancer
9 tracked EGFR x c-MET drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the EGFR x c-MET page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 approved / phase 43 Phase 21 Phase 1/22 Phase 11 preclinical / unstaged
Head-to-head evidence: 225Ac-FPI-2068 vs Amivantamab · 225Ac-FPI-2068 vs EMB-01 · ALK202 vs Amivantamab · ALK202 vs EMB-01 · Amivantamab vs AZD9592 · AZD9592 vs EMB-01